Hikma presents R&D pipeline of more than 330 products

Bitget2026/10/20 12:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hikma Pharmaceuticals has more than 330 products in development, targeting an addressable market exceeding $100 billion.
Epinephrine nasal spray is slated for US filing in the second half of 2026.
Generic Ellipta dry powder inhaler filing is targeted for 2029, addressing an approximately $11 billion market.
Generic Respimat soft mist inhaler filing is targeted for 2028, addressing an approximately $2 billion market.
Low global warming potential pressurized metered-dose inhalers are targeted for filing in 2028, addressing an approximately $9 billion market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hikma presents R&D pipeline of more than 330 products

You may also like

Crypto prices